IP Library › Granted Patent US 12,312,582
Granted Patent B2
US 12,312,582 · App. 17/211,484 · Granted May 27, 2025

Method for isolation of nucleic acid containing particles and extraction of nucleic acids therefrom

Inventors: Johan Karl Olov Skog (Lincoln, MA); Leileata M. Russo (New York, NY)
Assignee: Exosome Diagnostics, Inc.
C12N15/1003B01D21/26B01D21/262
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,312,582
App. No.
17/211,484
Granted
May 27, 2025
Kind
B2
Abstract

A method for extracting nucleic acids from a biological sample by isolating nucleic acid-containing particles from the biological sample by one or more centrifugation procedures, performing one or more steps to mitigate adverse factors that prevent or might prevent high quality nucleic acid extraction, and extracting nucleic acids from the isolated particles. The centrifugation procedures are performed at a speed not exceeding about 200,000 g. The extracted nucleic acids contain both 18S and 28S rRNA.

Claims (20)

1. A method for extracting nucleic acids from a biological sample from a subject, comprising the steps of:

a) isolating microvesicles comprising exosomes from the biological sample by one or more centrifugation procedures to pellet the microvesicles from the biological sample and generate isolated, pelleted microvesicles comprising exosomes, wherein none of the centrifugation procedures are performed at a speed exceeding 20,000 g;

and b) extracting nucleic acids from the isolated, pelleted microvesicles comprising exosomes, wherein the extracted nucleic acids comprise 18S and 28S rRNAs.

2. The method of claim 1 , wherein the biological sample is a body fluid.

3. The method of claim 2 , wherein the body fluid is a serum sample from the subject.

4. The method of claim 2 , wherein the body fluid is a urine sample from the subject.

5. The method of claim 2 , wherein the body fluid is a spinal fluid sample from the subject.

6. The method of claim 1 , wherein the subject is a human.

7. The method of claim 1 , wherein the subject is a non-human mammal.

8. The method of claim 1 , wherein the extracted nucleic acids comprise RNA.

9. The method of claim 1 , wherein the extracted nucleic acids comprise DNA.

10. The method of claim 1 , wherein the extracted nucleic acids comprise both RNA and DNA.

11. The method of claim 1 , wherein a nucleic acid comprising GAPDH is in the extracted nucleic acids.

12. The method of claim 1 , wherein 18S and 28S rRNAs are in the extracted nucleic acids in a ratio of about 0.5 to about 1.0.

13. The method of claim 1 , wherein 18S and 28S rRNAs are detectable in the extracted nucleic acids in a ratio of about 0.5.

14. The method of claim 8 , further comprising treating the biological sample and/or the isolated microvesicles with DNase.

15. The method of claim 8 , further comprising treating the biological sample and/or the isolated microvesicles with RNase inhibitor and DNase.

16. The method of claim 1 , further comprising treating the isolated microvesicles with RNase inhibitor.

17. The method of claim 1 , further comprising treating the biological sample with RNase inhibitor before isolating the microvesicles.

18. The method of claim 1 , further comprising, prior to step a), pre-processing the biological sample with one or more centrifugation or filtration steps to pellet or capture large particles and debris while the microvesicles comprising exosomes remain in solution.

Assignments (4)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 10, 2026
From: EXOSOME DIAGNOSTICS, INC.
To: EXACT SCIENCES CORPORATION
Reel/Frame 075391/0617 →
RELEASE OF SECURITY INTEREST Recorded Jan 13, 2026
From: ORC SPV LLC
To: EXOSOME DIAGNOSTICS, INC.
Reel/Frame 073452/0001 →
SECURITY INTEREST Recorded Sep 29, 2025
From: EXOSOME DIAGNOSTICS, INC.
To: ORC SPV LLC
Reel/Frame 072403/0019 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 9, 2022
From: SKOG, JOHAN KARL OLOV; RUSSO, LEILEATA M.
To: EXOSOME DIAGNOSTICS, INC.
Reel/Frame 058940/0034 →
Continuity (4)
Continuation 14877531 · Oct 7, 2015
Continuation 13883673
Provisional Application 61412369 · Nov 10, 2010
Related Publication 20210207124A1 · Jul 8, 2021
References Cited (357)
US 5219727A · Wang et al. · 1993 [cited by applicant]
US 5538871A · Nuovo et al. · 1996 [cited by applicant]
US 5547859A · Goodman · 1996 [cited by applicant]
US 5556773A · Yourno · 1996 [cited by applicant]
US 5582981A · Toole et al. · 1996 [cited by applicant]
US 5639606A · Willey · 1997 [cited by applicant]
US 5639611A · Wallace et al. · 1997 [cited by applicant]
US 5811250A · Solum · 1998 [cited by applicant]
US 5840867A · Toole et al. · 1998 [cited by applicant]
US 6004755A · Wang · 1999 [cited by applicant]
US 6204375B1 · Lader · 2001 [cited by applicant]
US 6329179B1 · Kopreski · 2001 [cited by applicant]
US 6525154B1 · Shea et al. · 2003 [cited by applicant]
US 6607898B1 · Kopreski et al. · 2003 [cited by applicant]
US 6759217B2 · Kopreski · 2004 [cited by applicant]
US 6794135B1 · Kopreski et al. · 2004 [cited by applicant]
US 6812023B1 · Lamparski et al. · 2004 [cited by applicant]
US 6893837B2 · Slamon et al. · 2005 [cited by applicant]
US 6899863B1 · Dhellin et al. · 2005 [cited by applicant]
US 6913879B1 · Schena · 2005 [cited by applicant]
US 6916634B2 · Kopreski · 2005 [cited by applicant]
US 6939671B2 · Kopreski · 2005 [cited by applicant]
US 6994960B1 · Foote et al. · 2006 [cited by applicant]
US 7074563B2 · Köster · 2006 [cited by applicant]
US 7186512B2 · Martienssen et al. · 2007 [cited by applicant]
US 7198893B1 · Köster et al. · 2007 [cited by applicant]
US 7198923B1 · Abrignani et al. · 2007 [cited by applicant]
US 7332533B2 · Kim · 2008 [cited by applicant]
US 7332552B2 · Benicewicz · 2008 [cited by applicant]
US 7332553B2 · Sellergren et al. · 2008 [cited by applicant]
US 7364848B2 · Van Beuningen et al. · 2008 [cited by applicant]
US 7378245B2 · Liu · 2008 [cited by applicant]
US 7384589B2 · Hart et al. · 2008 [cited by applicant]
US 7671010B2 · Arap et al. · 2010 [cited by applicant]
US 7691383B2 · Chakrabarty et al. · 2010 [cited by applicant]
US 7776523B2 · Garcia · 2010 [cited by applicant]
US 7807183B2 · Hong et al. · 2010 [cited by applicant]
US 10988755B2 · Skog et al. · 2021 [cited by applicant]
US 20020106684A1 · Kopreski · 2002 [cited by applicant]
US 20030077808A1 · Rosen · 2003 [cited by applicant]
US 20050003426A1 · Ranum et al. · 2005 [cited by applicant]
US 20050250100A1 · Hayashizaki · 2005 [cited by applicant]
US 20060081516A1 · Hendrickson · 2006 [cited by applicant]
US 20060099605A1 · Hall, Jr. · 2006 [cited by examiner]
US 20060116321A1 · Robbins et al. · 2006 [cited by applicant]
US 20060160087A1 · McGrath et al. · 2006 [cited by applicant]
US 20060223072A1 · Boyes et al. · 2006 [cited by applicant]
US 20070104738A1 · Tatischeff et al. · 2007 [cited by applicant]
US 20070105105A1 · Clelland · 2007 [cited by applicant]
US 20070254351A1 · Abrignani et al. · 2007 [cited by applicant]
US 20070298118A1 · Lotvall et al. · 2007 [cited by applicant]
US 20080003575A1 · Michalik et al. · 2008 [cited by applicant]
US 20080268429A1 · Pietrzkowski et al. · 2008 [cited by applicant]
US 20080287669A1 · Braman et al. · 2008 [cited by applicant]
US 20090169636A1 · O'Hagan et al. · 2009 [cited by applicant]
US 20090220944A1 · Fais et al. · 2009 [cited by applicant]
US 20090227533A1 · Bader · 2009 [cited by applicant]
US 20100008978A1 · Drummond et al. · 2010 [cited by applicant]
US 20100062428A1 · Allen · 2010 [cited by examiner]
US 20100075315A1 · Pietrzkowski · 2010 [cited by applicant]
US 20100184046A1 · Klass · 2010 [cited by applicant]
US 20100196426A1 · Skog et al. · 2010 [cited by applicant]
US 20100209355A1 · Chakrabarty et al. · 2010 [cited by applicant]
US 20100255514A1 · Rak · 2010 [cited by applicant]
US 20110003704A1 · Skog et al. · 2011 [cited by applicant]
US 20110053157A1 · Skog et al. · 2011 [cited by applicant]
US 20110081651A1 · Hillan · 2011 [cited by applicant]
US 20110195426A1 · Russo et al. · 2011 [cited by applicant]
US 20120115160A1 · D'Souza-Schorey · 2012 [cited by applicant]
US 20120142001A1 · Skog et al. · 2012 [cited by applicant]
US 20120238467A1 · Taylor · 2012 [cited by applicant]
US 20130040833A1 · Noerholm et al. · 2013 [cited by applicant]
US 20130131194A1 · Skog et al. · 2013 [cited by applicant]
US 20130295574A1 · Skog et al. · 2013 [cited by applicant]
US 20140147839A1 · Chen et al. · 2014 [cited by applicant]
US 20140194319A1 · Skog et al. · 2014 [cited by applicant]
US 20140194613A1 · Skog et al. · 2014 [cited by applicant]
US 20160024491A1 · Skog et al. · 2016 [cited by applicant]
US 20160348095A1 · Russo et al. · 2016 [cited by applicant]
US 20160362678A1 · Skog et al. · 2016 [cited by applicant]
US 20170114389A1 · Russo et al. · 2017 [cited by applicant]
US 20170314075A1 · Skog et al. · 2017 [cited by applicant]
US 20180051335A9 · Skog et al. · 2018 [cited by applicant]
CA 2453198A1 · 2005 [cited by applicant]
CA 2676113A1 · 2009 [cited by applicant]
CA 2699646A1 · 2009 [cited by applicant]
CN 101085349A · 2007 [cited by applicant]
EP 2202522A1 · 2010 [cited by applicant]
JP H08509806A · 1996 [cited by applicant]
JP 2002521071A · 2002 [cited by applicant]
JP 2002535665A · 2002 [cited by applicant]
JP 2003514523A · 2003 [cited by applicant]
JP 2003531864A · 2003 [cited by applicant]
JP 2008501336A · 2008 [cited by applicant]
JP 2008035779A · 2008 [cited by applicant]
JP 2008509806A · 2008 [cited by applicant]
JP 2008541699A · 2008 [cited by applicant]
JP 2010534480A · 2010 [cited by applicant]
JP 2011510663A · 2011 [cited by applicant]
JP 2012533308A · 2012 [cited by applicant]
JP 5156829B2 · 2013 [cited by applicant]
WO WO1994011018A1 · 1994 [cited by applicant]
WO WO1994022018A1 · 1994 [cited by applicant]
WO WO2000004194A1 · 2000 [cited by applicant]
WO WO2000006780A1 · 2000 [cited by applicant]
WO WO2001036601A1 · 2001 [cited by applicant]
WO WO2001082958A2 · 2001 [cited by applicant]
WO WO2002099064A2 · 2002 [cited by applicant]
WO WO2003023065A1 · 2003 [cited by applicant]
WO WO2003050290A2 · 2003 [cited by applicant]
WO WO2003076603A2 · 2003 [cited by applicant]
WO WO2005000098A3 · 2005 [cited by applicant]
WO WO2005081867A3 · 2005 [cited by applicant]
WO WO2005121359A1 · 2005 [cited by applicant]
WO WO2005121369A2 · 2005 [cited by applicant]
WO WO2006020707A2 · 2006 [cited by applicant]
WO WO2006048291A2 · 2006 [cited by applicant]
WO WO2006113590A2 · 2006 [cited by applicant]
WO WO2006119439A2 · 2006 [cited by applicant]
WO WO2007015174A2 · 2007 [cited by applicant]
WO WO2007103572A2 · 2007 [cited by applicant]
WO WO2007126386A1 · 2007 [cited by applicant]
WO WO2007127848A1 · 2007 [cited by applicant]
WO WO2008084331A2 · 2008 [cited by applicant]
WO WO2008104543A2 · 2008 [cited by applicant]
WO WO2009015357A1 · 2009 [cited by applicant]
WO WO2009021322A1 · 2009 [cited by applicant]
WO WO2009030029A1 · 2009 [cited by applicant]
WO WO2009036236A1 · 2009 [cited by applicant]
WO WO2009092386A2 · 2009 [cited by applicant]
WO WO2009100029A1 · 2009 [cited by applicant]
WO WO2009155505A2 · 2009 [cited by applicant]
WO WO2010028099A1 · 2010 [cited by applicant]
WO WO2010056337A2 · 2010 [cited by applicant]
WO WO2010065968A1 · 2010 [cited by applicant]
WO WO2010099184A1 · 2010 [cited by applicant]
WO WO2010141955A2 · 2010 [cited by applicant]
WO WO2011000551A1 · 2011 [cited by applicant]
WO WO2011009104A1 · 2011 [cited by examiner]
WO WO2011031877A1 · 2011 [cited by applicant]
WO WO2011031892A1 · 2011 [cited by applicant]
WO WO2011088226A2 · 2011 [cited by applicant]
WO WO2011127219A1 · 2011 [cited by applicant]
WO WO2012031008A2 · 2012 [cited by applicant]
WO WO2012051622A2 · 2012 [cited by applicant]
WO WO2012064993A1 · 2012 [cited by applicant]
Abravaya, et al., “Detection of point mutations with a modified ligase chain reaction (Gap-LCR).” Nucleic Acids Research (1995); 23(4): 675-682. [cited by applicant]
Affymetriix, “GeneChip Human Genome U133 Set”, Apr. 20, 2001, 2 pages, URL: http://www.affymetrix.com/products/arrays/specific/hgu_133_.asp. [cited by applicant]
Alessi et al., “New insights into mTOR signaling: mTORC2 and beyond”, Sci Signal 2(67) pe27 (2009). [cited by applicant]
Allawi et al., “Quantitation of microRNAs using a modified Invader assay.” RNA, 10:1153-1161 (2004). [cited by applicant]
Al-Nedawi, et al., “Intercellular transfer of the oncogenic receptor EGFRvIII by microvesicles derived from tumour cells.” Nat Cell Biol. (2008); 10(5): 619-624. [cited by applicant]
Alvarez, et al., “Comparison of protein, microRNA, and mRNA yields using different methods of urinary exosome isolation for the discovery of kidney disease biomarkers.” Kidney Int. Nov. 2012; 82(9):1024-1032. Epub Jul. … [cited by applicant]
Ason et al., “Differences in vertebrate microRNA expression.” PNAS, 103(39):14385-14389 (2006). [cited by applicant]
Baj-Krzyworzeka et al., “Tumour-derived microvesicles carry several surface determinants and mRNA of tumour cells and transfer some of these determinants to monocytes.” Cancer Immunology, Immunotherapy, 55(7):808-818 (2… [cited by applicant]
Balzar, et al., “The biology of the 17-1A antigen (Ep-CAM).” J Mol Med. (1999); 77(10): 699-712. [cited by applicant]
Bamford et al., “The COSMIC (Catalogue of Somatic Mutations in Cancer) database and website”, Br J Cancer 91 (2): 355-358 (2004). [cited by applicant]
Benner et al., “Evolution, language and analogy in functional genomics.” Trends in Genetics, 17:414-418 (2001). [cited by applicant]
Bergsmedh et al., “Horizontal transfer of oncogenes by uptake of apoptotic bodies”, Proc Natl Acad Sci USA 98(11) 6407-6411 (2001). [cited by applicant]
Bess, et al., “Microvesicles are a source of contaminating cellular proteins found in purified HIV-1 preparations.” Virology (Mar. 1997); 230(1):134-44. [cited by applicant]
Biernat, et al., “Predominant Expression of Mutant EGFR (EGFRvIII) is Rare in Primary Glioblastomas.” Brain Pathol (2004); 14: 131-136. [cited by applicant]
Booth et al., “Exosomes and hiv gag bud from endosome-like domains of the t cell plasma membrane.” J Cell Biol., 172(6): 923-935 (2006). Published Online: Mar. 13, 2006. [cited by applicant]
Bossi et al., “Molecularly imprinted polymers for the recognition of proteins: The state of the art.” Biosensors and Bioelectronics (2007); 22(6): 1131-1137. [cited by applicant]
Bratthauer et al., “Expression of LINE-1 retrotransposons in human breast cancer”, Cancer 73(9) 2333-2336 (1994). [cited by applicant]
Burghoff et al., “Horizontal gene transfer from human endothelial cells to rat cardiomyocytes after intracoronary ransplantation”, Cardiovasc Res 77(3) 534-543 (2008). online publish-ahead-of-print Nov. 13, 2007. [cited by applicant]
Cadieux et al., “Genome-wide hypomethylation in human glioblastomas associated with specific copy number alteration, methylenetetrahydrofolate reductase allele status, and increased proliferation”, Cancer Res 66(17) 846… [cited by applicant]
Carr et al., “Circulating membrane vesicles in leukemic blood”, Cancer Res 45(11 Pt 2) 5944-5951 (1985). [cited by applicant]
Cermelli et al., “Circulating microRNAs in patients with chronic hepatitis C and non-alcoholic fatty liver disease.” PLoS One, 6(8):e23937 (2011). [cited by applicant]
Chabert et al., “Cell culture of tumors alters endogenous poly(ADPR)polymerase expression and activity”, Int J Cancer (1993); 53(5): 837-842. [cited by applicant]
Chaput et al., “The potential of exosomes in immunotherapy.” Expert Opin Biol Ther., 5(6):737-747 (2005). [cited by applicant]
Chen et al., “Real-time quantification of microRNAs by stem-loop RT-PCR.” Nucleic Acid Research, 33(20):e179 (2005). [cited by applicant]
Chen, et al., “Microfluidic isolation and transcriptome analysis of serum microvesicles.” Lab Chip (2010); 10(4): 505-511. [cited by applicant]
Chen, et. al., “Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases.” Cell Research (2008); 18: 997-1006. [cited by applicant]
Cheng et al., “Advances of AKT pathway in human oncogenesis and as a target for anti-cancer drug discovery”, Curr Cancer Drug Targets 8(1) 2-6 (2008). [cited by applicant]
Cheruvanky, et al., “Rapid isolation of urinary exosomal biomarkers using a nanomembrane ultrafiltration concentrator.” Am J Physiol Renal Physiol. (2007); 292: F1657-F1661. [cited by applicant]
Cheung et al., “Natural variation in human gene expression assessed in lymphoblastoid cells.” Nature Genetics, 33:422-425 (2003). [cited by applicant]
Cho et al., “Hypermethylation of CpG island loci and hypomethylation of LINE-1 and Alu repeats in prostate adenocarcinoma and their relationship to clinicopathological features”, J Pathol 211 (3) 269-277 (2007). [cited by applicant]
Choi, et al., “Proteomic Analysis of Microvesicles Derived from Human Colorectal Cancer Cells.” Journal of Proteome Rsearch (2007); 6: 4646-4655. [cited by applicant]
Choi, et al., “Proteomic analysis of microvesicles derived from human colorectal cancer ascites.” Proteomic (2011); 11 (13): 2745-2751. [cited by applicant]
Ciafrè et al., “Extensive modulation of a set of microRNAs in primary glioblastoma.” Biochemical and Biophysical Research Communications, 334:1351-1358 (2005). [cited by applicant]
Clayton et al., “Human tumor-derived exosomes selectively impair lymphocyte responses to interleukin-2.” Cancer Res., 67(15):7458-7466 (2007). [cited by applicant]
Cocucci, et al., “Shedding microvesicles: artefacts no more.” Trends in Cell Biology (2009); 19 (2): 43-51. [cited by applicant]
Contreras-Galindo et al., “Human endogenous retrovirus K (HML-2) elements in the plasma of people with ymphoma and breast cancer”, J Virol 82(19) 9329-9336 (2008). [cited by applicant]
Cooperberg, et al., “The Changing Face of Low-risk Prostate Cancer: Trends in Clinical Presentation and Primary Management.” J Clin Oncolog (2004); 22 (11): 2141-2149. [cited by applicant]
Corsten et al., “Circulating MicroRNA-208b and MicroRNA-499 Reflect Myocardial Damage in Cardiovascular Disease.” Circulation Cardiovascular Genetics, 2:499-506 (2010). [cited by applicant]
Cortez and Calin, “MicroRNA identification in plasma and serum: a new tool to diagnose and monitor diseases”, Expert Opin Biol Ther 9(6) 703-711 (2009). [cited by applicant]
Cotton, et al., “Reactivity of cytosine and thymine in single-base-pair mismatches with hydroxylamine and osmium tetroxide and its application to the study of mutations.” Proc Natl Acad Sci U S A (1988); 85 (12): 4397-4… [cited by applicant]
Cowell et al., “Application of oligonucleotides arrays for coincident comparative genomic hybridization, ploidy status and loss of heterozygosity studies in human cancers”, Methods Mol Biol 556: 47-65 (2009). [cited by applicant]
Daskalos et al., “Hypomethylation of retrotransposable elements correlates with genomic instability in non-small cell lung cancer.” Int J Cancer 124(1) 81-87 (2009). [cited by applicant]
Day et al., “PCA3: from basic molecular science to the clinical lab”, Cancer Lett 301(1) 1-6 (2011). [cited by applicant]
Deregibus et al., “Endothelial progenitor cell-derived microvesicles activate an angiogenic program in endothelial cells by a horizontal transfer of mRNA”, Blood 110(7) 2440-2448 (2007). [cited by applicant]
Dermer “Another anniversary for the war on cancer.” Nature Biotechnology 12(3):320 (1994). [cited by applicant]
Diehl et al., “BEAMing: single-molecule PCR on microparticles in water-in-oil emulsions”, Nat Methods 3(7) 551-559 (2006). [cited by applicant]
Diehl et al., “Circulating mutant DNA to assess tumor dynamics.” Nat Med., 14(9):985-999 (2008). [cited by applicant]
Diehl et al., “Detection and quantification of mutations in the plasma of patients with colorectal tumors.” PNAS (2005); 102(45): 16268-16373. [cited by applicant]
Dowling et al., “mTORC1-mediated cell proliferation, but not cell growth, controlled by the 4E-BPs”, Science 328 (5982) 1172-1176 (2010). [cited by applicant]
Dressman et al., “Transforming single DNA molecules into fluorescent magnetic particles for detection and enumeration of genetic variations”, Proc Nall Acad Sci USA 100(15) 8817-S822 (2003). [cited by applicant]
Duijvesz et al., “Exosomes as biomarker treasure chests for prostate cancer”, Eur Urol 59(5) 823-831 (2011). [cited by applicant]
Eastham et al., “Relationship between clonogenic cell survival, DNA damage and chromosomal radiosensitivity in nine human cervix carcinoma cell lines” Int. Journal Radial. Biol (2001); 77(3): 295-302. [cited by applicant]
El-Hefnawy, et al., “Characterization of amplifiable, circulating RNA in plasma and its potential as a tool for cancer diagnostics.” Clinical Chemistry, 50(3): 564-573 (2004). [cited by applicant]
Estécio et al., “LINE-1 Hypomethylation in Cancer Is Highly Variable and Inversely Correlated with Microsatellite Instability”, PLoS One 2(5) e399 (2007). [cited by applicant]
Extended European Search Report for European Patent Application No. 11839005.3, dated Mar. 27, 2014, 8 pages. [cited by applicant]
Fabbri et al., “MicroRNA-29 family reverts aberrant methylation in lung cancer by targeting DNA methyltransferases 3A and 3B.” PNAS, 104(40):15805-15810 (2007). [cited by applicant]
Fernandez-Llama, et al., “Tamm-Horsfall protein and urinary exosome isolation.” Kidney Int. (Apr. 2010); 77(8):736-742. Epub Feb. 3, 2010. [cited by applicant]
Fiorentino et al., “The minisequencing method: an alternative strategy for preimplantation genetic diagnosis of single gene disorders”, Mol Human Reprod 9(7) 399-410 (2003). [cited by applicant]
Fischer and Lerman, “[11] Two-dimensional electrophoretic separation of restriction enzyme fragments of DNA.” Methods in Enzymology (1979); 68: 183-191. [cited by applicant]
Fischer and Lerman, “Length-independent separation of DNA restriction fragments in two-dimensional gel electrophoresis.” Cell (1979); 16(1): 191-200. [cited by applicant]
Forbes et al., “COSMIC (the Catalogue of Somatic Mutations in Cancer): a resource to investigate acquired mutations in human cancer”, Nucleic Acids Res 38(Database issue) D652-D657 (2010). [cited by applicant]
Forbes et al., “COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer”, Nuclec Acids Res 39(Database issue) D945-D950 (2011). [cited by applicant]
Forbes et al., “The Catalogue of Somatic Mutations in Cancer (COSMIC)”, Supplement 57:Unit-10.11, 32 pages (2008). [cited by applicant]
Furnari, et al., “Malignant astrocytic glioma: genetics, biology, and paths to treatment.” Genes & Dev. (2007); 21: 2683-2710. [cited by applicant]
Gambim, et al., “Platelet-derived exosomes induce endothelial cell apoptosis through peroxynitrite generation: experimental evidence for a novel mechanism of septic vascular dysfunction”, Crit Care 11 (5) R 107 (2007). [cited by applicant]
Geiss et al., “Direct multiplexed measurement of gene expression with color-coded probe pairs.” Nat Biotechnol. (2008); 26 (3): 317-325. [cited by applicant]
GenBank (Accession NM_005896) submitted Jan. 31, 2003, 4 pages. [cited by applicant]
Gene Annot, “Probes for MYC availible on Affymetrix arrays HG-U95, HG-U 133, HG-U 133 Plus 2.0”, Weizmann Institute of Science found at URL http://genecards.weizmann.ac.il/cgi-bin/geneannot/ga_search.pl (Apr. 20, 2001, … [cited by applicant]
Ginestra et al., “The amount and proteolytic content of vesicles shed by human cancer cell lines correlates with their in vitro invasiveness.” Anticancer Research, 18(5A): 3433-3437 (1998). [cited by applicant]
Golan et al., “Human endogenous retrovirus (HERV-K) reverse transcriptase as a breast cancer prognostic marker”, Neoplasia 10(6) 521-533 (2008). [cited by applicant]
Gonzales, et. al., “Urinary exosomes: is there a future?” Nephrol Dial Transplant (2008); 23 (6): 1799-1801. [cited by applicant]
Goodier and Kazazian, Jr., “Retrotransposons Revisited: The Restraint and Rehabilitation of Parasites”, Cell 135(1) 23-35 (2008). [cited by applicant]
Gormally et al., “Circulating free dna in plasma or serum as biomarker of carcinogenesis: practical aspects and biological significance.” Mutat Res., 635:105-117 (2007). [cited by applicant]
Grant, et al., “The Proteins of Normal Urine.” The Proteins of Normal Urine Journal of Clinical Pathology 1957;10:360-368. [cited by applicant]
Greco, et al., “Argosomes: a potential vehicle for the spread of morphogens through epithelia.” Cell., 106 (5): 633-645 (2001). [cited by applicant]
Green et al., “The prognostic significance of IDH1 mutations in younger adult patients with acute myeloid leukemia is dependent on FLT3/ITD status”, Blood 116(15) 277-2782 (2010). [cited by applicant]
Groskopf et al., “Aptima pca3 molecular urine test: development of a method to aid in the diagnosis of prostate cancer.” Clin Chem., 52(6):1089-1095 (2006). [cited by applicant]
Guatelli, et al., “Isothermal, in vitro amplification of nucleic acids by a multienzyme reaction modeled after retroviral replication.” Proc Natl Acad Sci U S A (1990); 87 (19): 1874-1878. [cited by applicant]
Guescini et al., “Astrocytes and Glioblastoma cells release exosomes carrying mtDNA”, J Neural Transm (2010); 117(1) 1-4. [cited by applicant]
Hahn, “Molecular biology of double-minute chromosomes.” BioEssays (1993); 15(7): 477-484. [cited by applicant]
Hanahan and Weinberg, “The hallmarks of cancer”, Cell 100(1) 57-70 (2000). [cited by applicant]
Hartman et al., “Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: impli… [cited by applicant]
Heimberger et al., “The natural history of EGFR and EGFRvIII in glioblastoma patients”, J Transl Med 3: 38 (2005). [cited by applicant]
Hessels et al., “DD3PCA3-based Molecular Urine Analysis for the Diagnosis of Prostate Cancer.” European Urology, 44:8-16 (2003). [cited by applicant]
Hessels, et. al., “Detection of TMPRSS2-ERG Fusion Transcripts and Prostate Cancer Antigen 3 in Urinary Sediments May Improve Diagnosis of Prostate Cancer.” Clin Cancer Res (2007); 13 (17): 5103-5108. [cited by applicant]
Hildebrant et al., “Genetic variations in the PI3K/PTEN/AKT/mTOR pathway are associated with clinical outcomes in esophageal cancer patients treated with chemoradiotherapy”, J Clin Oncol 27(6) 857-871 (2009). [cited by applicant]
Holdhoff et al., “Analysis of Circulating Tumor DNA to Confirm Somatic KRAS Mutations.” J Natl Cancer Inst 101(18) 1284-1285 (2009). [cited by applicant]
Hunter, et al., “Detection of microRNA Expression in Human Peripheral Blood Microvesicles.” PLoS One. 2008; 3(11 ):e3694. Epub Nov. 11, 2008. (Year: 2008). [cited by applicant]
Iero et al., “Tumour-released exosomes and their implications in cancer immunity.” Cell Death and Differentiation, 15:80-88 (2008). [cited by applicant]
Iorio et al., “MicroRNA signatures in human ovarian cancer.” Cancer Research, 67(18):8699-8707 (2007). [cited by applicant]
Itadani Et al., “Can systems biology understand pathway activation? Gene expression signatures as surrogate markers for understanding the complexity of pathway activation”, Curr Genomics 9(5) 349-360 (2008). [cited by applicant]
Jacquillet, et al., “Urinary vesicles: in splendid isolation.” Nephrol Dial Transplant. Jun. 2013; 28(6):1332-1335. Epub Jan. 24, 2013. [cited by applicant]
Janowska-Wieczorek et al., “Microvesicles derived from activated platelets induce metastasis and angiogenesis in lung cancer.” Int J Cancer., 113 (5): 752-760 (2005). [cited by applicant]
Ji et al., “MALAT-1, a novel noncoding RNA, and thymosin β4 predict metastasis and survival in early-stage non-small cell lung cancer”, Oncogene 22(39) 8031-8041 (2003). [cited by applicant]
Johnson et al., “Surface-immobilized peptide aptamers as probe molecules for protein detection.” Anal Chem., 80:978-983 (2008). [cited by applicant]
Jones et al., “Core signaling pathways in human pancreatic cancers revealed by global genomic analyses.” Science, 321(5897):1801-1806 (2008). [cited by applicant]
Kan and Dozy, “Antenatal diagnosis of sickle-cell anaemia by DNA analysis of amniotic-fluid cells.” The Lancet (1978); 312(8096): 910-912. [cited by applicant]
Kan and Dozy, “Polymorphism of DNA sequence adjacent to human β-globin structural gene: relationship to sickle mutation.” PNAS (1978); 75(11): 5631-5635. [cited by applicant]
Kang et al., “Mutational analysis of IDH1 codon 132 in glioblastomas and other common cancers”, Int J Cancer 125 (2) 353-355 (2009). [cited by applicant]
Kato et al., “A monoclonal antibody IMab-1 specifically recognizes IDH1R132H, the most common glioma-derived mutation”, Biochem Biophys Res Commun 390(3) 547-551 (2009). [cited by applicant]
Katoh and Kurata, “Association of endogenous retroviruses and long terminal repeats with human disorders”, Frontiers in Oncology (2013) 3 (234): 1-8. [cited by applicant]
Keller, et al., “CD24 is a marker of exosomes secreted into urine and amniotic fluid.” Kidney Int. (2007); 72 (9): 1095-1102. [cited by applicant]
Keller, et al., “Exosomes: From biogenesis and secretion to biological function.” Immunology Letters (2006); 107: 102-108. [cited by applicant]
Kislauskis et al., “Sequences Responsible for Intracellular Localization of β-Actin Messenger RNA Also Affect Cell Phenotype.” J Cell Biol., 127:441-451 (1994). [cited by applicant]
Kleiman et al., “HERV-K(HML-2) GAG/ENV antibodies as indicator for therapy effect in patients with germ cell tumors.” Int J Cancer 110(3) 459-461 (2004). [cited by applicant]
Klein et al., “Combined transcriptome and genome analysis of single microstatic cells.” Nature Biotechnology, 20:387-392 (2002). [cited by applicant]
Klemke et al., “Regulation of Cell Motility by Mitogen-activated Protein Kinase”, J Cell Biol 137(2) 481-492 (1997). [cited by applicant]
Koga, et. al., “Purification, Characterization and Biological Significance of Tumor derived Exosomes.” Anticancer Research (2005); 25 (6A): 3703-3708. [cited by applicant]
Kosaka et al., “Circulating microRNA in body fluid: a new potential biomarker for cancer diagnosis and prognosis”, Cancer Sci 101(10) 2087-2092 (2010). [cited by applicant]
Kristensen and Hansen, “PCR-based methods for detecting single-locus DNA methylation biomarkers in cancer diagnostics, prognostics, and response to treatment”, Clin Chem 55(8) 1471-1483 (2009). [cited by applicant]
Krupp, G., “Stringent RNA quality control using the Agilent 2100 bioanalyzer.” Application note, Agilent Technologies, Feb. 1, 2005, 8 pages, retrieved from the Internet http://www.chem.agilent.com/library/applications/… [cited by applicant]
Kwoh, et al., “Transcription-based amplification system and detection of amplified human immunodeficiency virus type 1 with a bead-based sandwich hybridization format.” Proc Natl Acad Sci U S A (1989); 86: 1173-1177. [cited by applicant]
Landegren, et al., “A ligase-mediated gene detection technique.” Science (1988); 241(4869): 1077-1080. [cited by applicant]
Laxman et al., “A first-generation multiplex biomarker analysis of urine for the early detection of prostate cancer.” Cancer Research, 68:645-649 (2008). [cited by applicant]
Lee et al., “Micro RNA expression and clinical outcome of small cell lung cancer.” PLoS One, 6(6):e21300 (2011). [cited by applicant]
Li, et al., “BEAMing up for detection and quantification of rare sequence variants.” Nat Methods. (2006); 3(2): 95-97. [cited by applicant]
Li, et al., “Replacing PCR with COLD-PCR enriches variant DNA sequences and redefines the sensitivity of genetic testing.” Nature Medicine (2008); 14(5): 579-584. [cited by applicant]
Liu et al., “Murine Mammary Carcinoma Exosomes Promote Tumor Growth by Suppression of NK Cell Function.” J Immunol., 176:1375-1385 (2006). [cited by applicant]
Liu, et al., “Reconstitution, activities, and structure of the eukaryotic RNA exosome.” Cell (2006); 127 (6): 1223-1237. [cited by applicant]
Lo and Chiu, “Prenatal diagnosis: progress through plasma nucleic acids,” Nat Rev Genet. (2007); 8(1): 71-77. [cited by applicant]
Lo et al., “Plasma placental RNA allelic ratio permits noninvasive prenatal chromosomal aneuploidy detection.” Nat Med., 13(2):218-223 (2007). [cited by applicant]
Lo, et al., “Automated gating offlow cytometry data via robust model-based clustering”, Cytometry 73(4) 321-332 (2008). [cited by applicant]
Löwer et al., “The viruses in all of us: Characteristics and biological significance of human endogenous retrovirus sequences”, Proc Nall Acad Sci USA 93(11) 5177-5184 (1996). [cited by applicant]
Mack et al., “Transfer of the chemokine receptor CCR5 between cells by membrane-derived microparticles: a mechanism for cellular human immunodeficiency virus 1 infection.” Nature Medicine, 6(7):769-775 (2000). [cited by applicant]
Maheswaran, et. al., “Detection of mutations in EGFR in circulating lung-cancer cells.” N Engl J Med. (2008); 359 (4): 366-377. [cited by applicant]
Mallardo et al., “Isolation and characterization of Staufen-containing ribonucleoprotein particles from rat brain.” Proc Natl Acad Sci USA, 100(4): 2100-2105 (2003). [cited by applicant]
Maron et al., “Gene expression analysis in pregnant women and their infants identifies unique fetal biomarkers that circulate in maternal blood.” J Clin Invest., 117(10): 3007-3019 (2007). [cited by applicant]
May “How Many Species Are there on Earth?”, Science 241(1) 1441-1449 (1998). [cited by applicant]
Mellinghoff, et al., “Molecular Determinants of the Response of Glioblastomas to EGFR Kinase Inhibitors.” The New England Journal of Medicine (2005); 353: 2012-2024. [cited by applicant]
Michael A, et al., “Exosomes from human saliva as a source of microRNA biomarkers.” Oral Dis. Jan. 2010; 16(1):34-8. Epub Jul. 15, 2009. (Year: 2010). [cited by applicant]
Miele, et al., “Autocatalytic replication of a recombinant RNA.” J Mol Biol. (1983); 171: 281-295. [cited by applicant]
Millimaggi et al., “Tumor vesicle-associated CD147 modulates the angiogenic capability of endothelial cells.” Neoplasia 9(4):349-357 (2007). [cited by applicant]
Miranda, et al., “Nucleic acids within urinary exosomes/microvesicles are potential biomarkers for renal disease.” Kidney International (2010); 78(2): 191-199. [cited by applicant]
Mitchell et al., “Can urinary exosomes act as treatment response markers in prostate cancer?”, J Transl Med 7: 4 (2009). [cited by applicant]
Modrek et al., “Genome-wide detection of alternatives splicing in expressed sequences of human genes”, Nucleic l\cids Research 29(13) 2850-2859 (2001). [cited by applicant]
Moscatello, et al., “Frequent Expression of a Mutant Epidermal Growth Factor Receptor in Multiple Human Tumors.” Cancer Research (1995); 55: 5536-5539. [cited by applicant]
Myers, et al., “Detection of single base substitutions by ribonuclease cleavage at mismatches in RNA:DNA duplexes.” Science (1985); 230(4731): 1242-1246. [cited by applicant]
Nagrath et al., “Isolation of rare circulating tumour cells in cancer patients by microchip technology.” Nature, 450(7173): 1235-1239 (2007). [cited by applicant]
Nakanishi, et. al., “PCA3 Molecular Urine Assay Correlates With Prostate Cancer Tumor Volume: Implication in Selecting Candidates for Active Surveillance.” The Journal of Urology (2008); 179 (5): 1804-1810. [cited by applicant]
Nakazawa, et al., “UV and skin cancer: specific p53 gene mutation in normal skin as a biologically relevant exposure measurement.” Proc Natl Acad Sci U S A. (1994); 91: 360-364. [cited by applicant]
Ng et al., “mRNA of placental origin is readily detectable in maternal plasma.” Proc Natl Acad Sci USA., 100(8):4748-4753 (2003). [cited by applicant]
Ng et al., “The concentration of circulating corticotropin-releasing hormone mRNA in maternal plasma is increased in preeclampsia.” Clin Chem. 49(5):727-731 (2003). [cited by applicant]
Nilsson, et al., “Prostate cancer-derived urine exosomes: a novel approach to biomarkers for prostate cancer.” British Journal of Cancer (2009); 100: 1603-1607. [cited by applicant]
Nishikawa et al., “Immunohistochemical analysis of the mutant epidermal growth factor, ΔEGFR, in glioblastoma.” Brain Tumor Pathol 21(2) 53-56 (2004). [cited by applicant]
Noerholm et al., “RNA expression patterns in serum microvesicles from patients with glioblastoma multiforme and controls”, BMC Cancer 12: 22 (2012). [cited by applicant]
Novakova et al., “MicroRNA involvement in glioblastoma pathogenesis”, Biochem Biophys Res Commun 386(1) 1-5 (2009). [cited by applicant]
Oliveira et al., “Distinct patterns of KRAS mutations in colorectal carcinomas according to gerrnline mismatch repair defects and hMLH1 methylation status”, Hum Mol Genet 13(19) 2303-2311 (2004). [cited by applicant]
Orita, et al., “Detection of polymorphisms of human DNA by gel electrophoresis as single-strand conformation polymorphisms.” PNAS (1989); 86(8): 2766-2770. [cited by applicant]
Orozco and Lewis, “Flow cytometric analysis of circulating microparticles in plasma.” Cytometry A (2010); 77A(6): 502-514. [cited by applicant]
Orozco, et al., “Membrane Protected Apoptotic Trophoblast Microparticles Contain Nucleic Acids.” The Amerian Journal of Pathology (2008); 173 (6): 1595-1608. [cited by applicant]
Ostrowski et al., “Rab27a and Rab27b control different steps of the exosome secretion pathway”, Nat Cell Biol 12 (1) 19-30 sup pp. 1-13 (2010). [cited by applicant]
Parsons et al., “An Integrated Genomic Analysis of Human Glioblastoma Multiforme.” Science, 321(5897): 1807-1821 (2008). [cited by applicant]
PCT/US2011/060251, International Preliminary Report on Patentability, dated May 14, 2013, 7 pages. [cited by applicant]
PCT/US2011/060251, International Search Report and Written Opinion, mailed Mar. 5, 2012, 9 pages. [cited by applicant]
Pelloski, et al., “Epidermal Growth Factor Receptor Variant III Status Defines Clinically Distinct Subtypes of Glioblastoma.” Journal of Clinical Oncology (2007); 25(16): 2288-2294. [cited by applicant]
Pisitkun, et al. Identification and proteomic profiling of exosomes in human urine. Proc Natl Acad Sci US A. Sep. 7, 2004; 101(36):13368-73. Epub Aug. 23, 2004. (Year: 2004). [cited by applicant]
Pisitkun, et. al., “Discovery of urinary biomarkers.” Mol Cell Proteomics (2006); 5 (10): 1760-1771. [cited by applicant]
Pleasance et al., “A comprehensive catalogue of somatic mutations from a human cancer genome”, Nature 463 (7278) 191-196 (2010). [cited by applicant]
Rak et al., “Genetic determinants of cancer coagulopathy, angiogenesis and disease progression”, Vnitr Lek 52(Suppl 1) 135-138 (2006). [cited by applicant]
Raposo, et al., “B lymphocytes secrete antigen-presenting vesicles.” Journal of Experimental Medicine (1996); 183: 1161-1172. [cited by applicant]
Ratajczak et al., “Membrane-derived microvesicles: important and underappreciated mediators of cell-to-cell communication.” Leukemia, 20:1487-1496 (2006). [cited by applicant]
Revenfeld et al., “Diagnostic and prognostic potential of extracellular vesicles in peripheral blood”, Clin Ther 36(6) 830-846 (2014). [cited by applicant]
Roman-Gomez et al., “Repetitive DNA hypomethylation in the advanced phase of chronic myeloid leukemia”, Leuk Res 32(3) 487-490 (2008). [cited by applicant]
Rood, IM, et al., Comparison of three methods for isolation of urinary microvesicles to identify biomarkers of nephrotic syndrome. Kidney Int. Oct. 2010; 78(8):810-6. Epub Aug. 4, 2010. (Year: 2010). [cited by applicant]
Ruprecht et al., “Endogenous retroviruses and cancer.” Cell Mol Life Sci 65(21) 3366-3382 (2008). [cited by applicant]
Ruprecht et al., “Human endogenous retrovirus family HERV-K(HML-2) RNA transcripts are selectively packaged into retroviral particles produced by the human germ cell tumor line Tera-1 and originate mainly from a proviru… [cited by applicant]
Ryan, et. al., “A prospective study of circulating mutant KRAS2 in the serum of patients with colorectal neoplasia: strong prognostic indicator in postoperative follow up.” Gut (2003); 52:101-108. [cited by applicant]
Saal and Harvey, “MicroRNAs and the kidney: coming of age.” Current Opinion in Nophrology and Hypertension, 18(4):317-323 (2009). [cited by applicant]
Saito-Hisaminto et al., “Genome-Wide Profiling of Gene Expression in 29 Normal Human Tissues with cDNA Microarray”, DNA Research (2002); 9: 35-45. [cited by applicant]
Sarbassov et al., “Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB”, Mol Cell 22(2) 159-168 (2006). [cited by applicant]
Schetter et al., “MicroRNA expression profiles associated with prognosis and therapeutic outcome in colon adenocarcinoma.” JAMA, 299(4):425-436 (2008). [cited by applicant]
Shinojima et al., “Prognostic value of epidermal growth factor receptor in patients with glioblastoma multiforme”, Cancer Res 63(20) 6962-6970 (2003). [cited by applicant]
Schmidt, et al., “QuantitativeMulti-Gene Expression Profiling of Primary Prostate Cancer.” The Prostate (2006); 66(14): 1521-1534. [cited by applicant]
Silva et al., “Selective gene silencing by viral delivery of short hairpin RNA”, Virol J 7: 248 (2010). [cited by applicant]
Simons and Raposo, “Exosomes—vesicular carriers for intercellular communication”, Curr Opin Cell Biol 21 (4) 575-581 (2009). [cited by applicant]
Simpson RJ, et al. “Proteomic profiling of exosomes: current perspectives.” Proteomics. Oct. 2008; 8(19):4083-99. (Year: 2008). [cited by applicant]
Singh et al., “Gene Expression correlates of clinical prostate cancer behavior”, Cancer Cell (2002); 1(2): 203-209. [cited by applicant]
Skog, et al., “Glioblastoma microvesicles transport RNA and proteins that promote tumour growth and provide diagnostic biomarkers.” Nature Cell Biology (2008); 10(12): 1470-1476. [cited by applicant]
Sliva and Schnierle, “Selective gene silencing by viral delivery of short hairpin RNA”, Virol J 7: 248 (2010). [cited by applicant]
Srikantan et al., “PCGEM1, a prostate-specific gene, is overexpressed in prostate cancer”, Proc Nall Acad Sci USA 97(22) 12216-12221 (2000). [cited by applicant]
Steemers, et al., “Whole-genome genotyping with the single-base extension assay.” Nature Methods (2006); 3: 31-33. [cited by applicant]
Stoorvogel, et al., “The Biogenesis and Functions of Exosomes.” Traffic (2002); 3 (5): 321-330. [cited by applicant]
Tam, W., “The emergent role of microRNAs in molecular diagnostics of cancer.” J Mol Diagn (2008); 10(5): 411-144. [cited by applicant]
Talor and Shah, “Methods of isolating extracellular vesicles impact down-stream analyses of their cargoes.” Methods. (Oct. 2015); 87: 3-10. Epub Mar. 10, 2015. [cited by applicant]
Taylor and Gercel-Taylor, “MicroRNA signatures of tumor-derived exosomes as diagnostic biomarkers of ovarian cancer.” Gynecol Oncol. (2008); 110: 13-21. [cited by applicant]
Taylor and Gercel-Taylor, “Tumour-derived exosomes and their role in cancer-associated T-cell signalling defects.” British Journal of Cancer, 92 (2): 305-311 (2005). [cited by applicant]
Tewes, et. al., “Molecular profiling and predictive value of circulating tumor cells in patients with metastatic breast cancer: an option for monitoring response to breast cancer related therapies.” Breast Cancer Res Tr… [cited by applicant]
The Cancer Genome Atlas (TCGA) Research Network, “Comprehensive genomic characterization defines human glioblastoma genes and core pathways”, Nature 455(7216) 1061-1068 (2008). [cited by applicant]
The International SNP Map Working Group., “A map of human genome sequence variation containing 1.42 million ingle nucleotide polymorphisms” Nature (2001); 409: 928-933. [cited by applicant]
Théry et al., “Isolation and characterization of exosomes from cell culture supernatants and biological fluids.” Curr Protoc Cell Biol. Chapter 3:Unit 3 22.1-3.22.29, (2006). [cited by applicant]
Théry, et al., “Exosomes: composition, biogenesis and function.” Nature Reviews Immunology (2002); 2 (8): 569-579. [cited by applicant]
Ting et al., “Aberrant overexpression of satellite repeats in pancreatic and other epithelial cancers”, Science 331 (6017) 593-596 (2011). [cited by applicant]
Tomlins et al., “Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer”, Science 310 (5748) 644-648 (2005). [cited by applicant]
Tullis, et al., “Calcium protects DNase I from proteinase K: a new method for the removal of contaminating RNase from DNase I.” Anal Biochem. (1980); 107(1): 260-264. [cited by applicant]
Valadi, et al., “Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells.” Nature Cell Biology (2007); 9: 654-659. [cited by applicant]
Van Dijk, et al., “Human cell growth requires a functional cytoplasmic exosome, which is involved in various mRNA decay pathways.” RNA (2007); 13: 1027-1035. [cited by applicant]
Velculescu, et al., “Serial Analysis of Gene Expression.” Science (1995); 270(5235): 484-487. [cited by applicant]
Voisset et al., “Human RNA “Rumor” Viruses: the Search for Novel Human Retroviruses in Chronic Disease.” Microbiol Mol Biol Rev 72(1) 157-196 (2008). [cited by applicant]
Wang-Johanning et al., “Human endogenous retrovirus K triggers an antigen-specific immune response in breast cancer patients”, Cancer Res 68(14) 5869-5877 (2008). [cited by applicant]
Went et al., “Frequent epcam protein expression in human carcinomas.” Hum Pathol., 35:122-128 (2004). [cited by applicant]
Wieckowski and Whiteside, “Human tumor-derived vs dendritic cell-derived exosomes have distinct biologic roles and molecular profiles.” Immunol Res., 36(1-3):247-254 (2006). [cited by applicant]
Wong et al., “Circulating placental RNA in maternal plasma is associated with a preponderance of 5′ mRNA fragments: implications for noninvasive prenatal diagnosis and monitoring.” Clin Chem., 51(10):1786-1795 (2005). [cited by applicant]
Wood et al., “The genomic landscapes of human breast and colorectal cancers.” Science, 318:1108-1113 (2007). [cited by applicant]
Wright and Lange, “Newer potential biomarkers in prostate cancer”, Rev Urol 9(4) 207-213 (2007). [cited by applicant]
Yan et al., “1DH1 and 1DH2 mutations in gliomas”, N Engl J Med 360(8) 765-773 (2009). [cited by applicant]
Yoshimoto et al., “Development of a real-lime RT-PCR assay for detecting EGFRvIII in glioblastoma samples”, Clin Cancer Res 14(2) 488-493 (2008). [cited by applicant]
Yu and Rak, “Shedding of tissue factor (TF)-containing microparticles rather than alternatively spliced TF is the main source of TF activity released from human cancer cells.” Journal of Thrombosis and Haemostatis (2004… [cited by applicant]
Yu et al., “Oncogenic events regulating tissue factor expression.” Haematological Reports, 1(9):18-20 (2005). [cited by applicant]
Yuan et al., “Transfer of MicroRNAs by Embryonic Stem Cell Microvesicles.” PLoS One 4(3) e4772 (2009). [cited by applicant]
Zhou, et al., “Collection, storage, preservation, and normalization of human urinary exosomes for biomarker discovery.” Kidney Int. (2006); 69(8): 1471-1476. [cited by applicant]
Moenner, et al., “Ribonuclease inhibitor protein of human erythrocytes: characterization, loss of activity in response to oxidative stress, and association with Heinz bodies,” Blood Cells Mol Dis. Jun. 1998; 24(2): 149-… [cited by applicant]